Corporate Profile

Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. Repare Therapeutics utilizes its proprietary, genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair.

Stock Quote


Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investor Relations

News Releases

07 Sep '21
Repare Therapeutics Appoints Thomas Civik to Its Board and as New Chairman
Former CEO of Five Prime Therapeutics brings over 25 years of leadership and commercial experience in pharma, biotech and molecular Dx CAMBRIDGE, Mass. & MONTREAL --(BUSINESS WIRE)--Sep. 7, 2021-- Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage

Recent Events

More events are coming soon.

Featured Reports